DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/c19520/bric_diabetes_drug) has announced the addition of the "BRIC Diabetes Drugs Market (2010-2015)" report to their offering.
The prevalence of diabetes is on the rise across the globe due to increased life expectancy, changing lifestyles, and the rising incidence of obesity. Brazil's diabetes drugs market is showing a double digit growth rate; while the Russian insulin market is also expected to witness significant growth with an estimated 20 million patients in the region requiring diabetes treatment by 2025.
India and China have the highest number of diabetics in the world, China alone is expected to have more than 71 million diabetic patients by 2025; and the similarly huge patient-base in India has already attracted a number of pharmaceutical companies such as Eli Lilly and Novo Nordisk. These companies are offering easy-to-use insulin versions to grab the market share in the Indian market for diabetes drugs. Thus, diabetes drugs market in BRIC economies is expected to have significant growth opportunities in the years to come.
Market Estimates and Forecasts:
The report categorizes the BRIC Diabetes Drugs market as follows:
- Injectables Market: (Insulin, exenatide)
- Oral Drugs Market: (Metformin, Sulfonylureas, thaizolidinediones, dipeptidyl inhibitors, meglitinides, alpha glucosidase inhibitors, combination medications)
- In addition to market tables for each submarket, each section of the report will provide market trends, drivers, and opportunities. The report also draws a competitive landscape, profiling the key players and the top-selling products in the diabetes drug market in BRIC.
What Makes our Reports Unique?:
- We provide the longest market segmentation chain in this industry - not many reports provide market breakdown up to level 5.
- We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.
- Comprehensive market analysis for the following sectors:
Pharmaceuticals, Medical Devices, Biotechnology, Semiconductor and Electronics, Energy and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT. We also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.
Key Questions Answered:
- Which are the high-growth segments/cash cows and how is the market segmented in terms of oral drugs, injectables?
- What are market estimates and forecasts; which markets are doing well and which are not?
- Where are the gaps and opportunities; what is driving the market?
- Which are the key playing fields? Which are the winning edge imperatives?
- How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?
Key Topics Covered:
1 Introduction
1.1 Key Takeaways
1.2 Report Description
1.3 Market Estimates And Forecasts
1.4 Stakeholders
1.5 Research Methodology
2 Summary
3 Market Overview
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Competitive Analysis, By Region
3.5 Competitive Analysis, By Segment
3.6 Competitive Analysis, By Products
3.7 Age Group Analysis
3.8 Key Findings
4 Market Analysis
4.1 Brazil Diabetes Drugs Market
4.2 Russia Diabetes Drugs Market
4.3 India Diabetes Market
4.4 China Diabetes Drugs Market
5 Anti-Diabetes Drugs Market
5.1 Injectables
5.2 Oral Antidiabetic Drugs
6 Competitive Landscape
6.1 BRIC Oad Market Share
6.2 BRIC Insulin Market Share
6.3 Evolution Of Anti-Diabetic Drugs
7 Company Profiles
Companies Mentioned:
- Abbott Laboratories
- Aurobindo Pharma Ltd
- Bayer Healthcare Ag
- Biocon Ltd
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Dr. Reddy's Laboratories Ltd
- Eli Lilly And Company
- Glenmark Pharmaceuticals Ltd
- Glaxosmithkline Plc
- Lupin Ltd
- Merck & Co. Inc.
- Novo Nordisk A/S
- Piramal Healthcare Ltd
- Ranbaxy Laboratories Ltd
- Roche Holding Ltd
- Sanofi-Aventis
- Shreya Life Sciences Pvt Ltd
- Sun Pharma Industries Ltd
- Takeda Pharmaceuticals Company
- Zydus Cadila Healthcare Ltd
For more information visit http://www.researchandmarkets.com/research/c19520/bric_diabetes_drug.